ClinicalTrials.gg
RecruitingNCT07375966RITIS-TNK2Updated Apr 1, 2026

Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)

A Phase 2 interventional study of Tenecteplase in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by General Hospital of Shenyang Military Region · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
48th of 59
198 · median 466
Started
2026
with 10 others
Phase 2
10 of 59
2 open now
Primary completion
2027-12
later than 13 of 31 live
Registered
50th of 59
by date
Lead sponsor
6 of 59
General Hospital of Shenyang Military Region

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 48th largest by planned enrollment, is one of 11 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 13 of the 31 other live ones, and was the 50th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

While intravenous thrombolysis (IVT) within 4.5 hours is the standard medical reperfusion therapy, its efficacy is limited, particularly for large or medium vessel occlusions (LVO/MeVO), with low recanalization rates for IVT with rt-PA. The newer thrombolytic agent, tenecteplase (TNK), offers practical advantages-including single bolus administration, a longer half-life, and potentially higher fibrin specificity-and has been shown to be non-inferior to rt-PA.

Despite advances, a significant proportion of patients with LVO/MeVO do not achieve early clinical improvement after standard IVT, likely due to persistent occlusion from a high thrombus burden. Endovascular therapy, while highly effective for LVO, has limited accessibility. Therefore, there is an urgent need for more effective and widely accessible pharmacological strategies.

This study proposes a rescue strategy based on the hypothesis that a second dose of IVT may improve outcomes in patients with imaging-confirmed LVO or MeVO who show no significant neurological improvement one hour after standard TNK thrombolysis (administered within 4.5 hours of stroke onset). The primary aim of this study is to formally evaluate the efficacy and safety of a repeated dose of intravenous tenecteplase in this specific patient population.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 year;
  • Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received standard-dose intravenous thrombolysis, and with no planned thrombectomy;
  • Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;
  • Baseline pc-ASPECTS/ASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI);
  • No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis;
  • Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA);
  • The second intravenous thrombolysis can be administered within 6 hours of onset;
  • First stroke onset or past stroke without obvious neurological deficit (mRS≤1);
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Planed for endovascular treatment;
  • Significant white matter hyperintensities (Fazekas score 3);
  • Any coagulation abnormality before the first thrombolysis, including > 1.5;
  • Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.;
  • Pregnancy;
  • Allergy to the drug(s);
  • Comorbidity with other serious diseases;
  • Participating in other clinical trials within 3 months;
  • Patients not suitable for the study considered by researcher.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    TNK group

    Tenecteplase is administered intravenously at a dose of 16 mg, with a maximum dose of 0.25 mg/kg.

    Drug: Tenecteplase

  • No intervention
    Control group

    no tenecteplase

Interventions

  • Tenecteplase is administered intravenously at a dose of 16 mg, with a maximum dose of 0.25 mg/kg.

06

What researchers measure

Primary outcomes

  1. rate of vessel recanalization

    Time frame: 24 (-6/+12) hours

Secondary outcomes

  1. proportion of excellent functional outcome (modified Rankin Scale (mRS) 0-1)

    The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome

    Time frame: 90±7 days

  2. proportion of favorable functional outcome (modified Rankin Scale (mRS) 0-2)

    The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome

    Time frame: 90±7 days

  3. ordinal distribution of modified Rankin Scale (mRS)

    The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome

    Time frame: 90±7 days

  4. occurrence of early neurological improvement (ENI)

    ENI is defined as more than 4-point decrease in National Institute of Health stroke scale score; the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome

    Time frame: 24 (-6/+12) hours

  5. change in National Institute of Health stroke scale (NIHSS) score

    the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome

    Time frame: 24 (-6/+12) hours

  6. change in National Institute of Health stroke scale (NIHSS) score

    the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome

    Time frame: 10±2 days

  7. all-cause mortality

    Time frame: 10±2 days

  8. occurence of symptomatic intracranial hemorrhage (sICH)

    Time frame: 24 (-6/+12) hours

  9. occurence of any intracranial hemorrhage

    Time frame: 24 (-6/+12) hours

  10. occurence of major systemic bleeding event

    Time frame: 24 (-6/+12) hours

  11. occurence of any bleeding event

    Time frame: 24 (-6/+12) hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 21 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 29, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07375966
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Jan 29, 2026
Start date
Mar 25, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Apr 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion